[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100431732":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":11,"centralContacts":19,"locations":25,"responsibleParty":156,"collaborators":11,"id":158,"slug":159,"hasResults":160,"nctId":161,"briefTitle":162,"officialTitle":163,"acronym":11,"eligibilityCriteria":164,"healthyVolunteers":160,"sex":165,"minAge":166,"maxAge":167,"enrollmentInfo":168,"targetDuration":11,"studyType":171,"phases":172,"briefSummary":174,"conditions":175,"keywords":178,"overallStatus":28,"whyStopped":11,"lastUpdateSubmitDate":186,"lastUpdatePostDateStruct":187,"startDateStruct":190,"completionDateStruct":192,"leadSponsor":194,"locationsCount":169},{"fullName":5,"class":6},"Apellis Pharmaceuticals, Inc.","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Pegcetacoplan","EXPERIMENTAL",null,[13],"Drug: Pegcetacoplan",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":11},"DRUG","Complement (C3) inhibitor",[9],[20],{"name":21,"role":22,"phone":23,"phoneExt":11,"email":24},"Apellis Clinical Trial Information Line","CONTACT","1-833-284-6361 (833-CT Info-1)","clinicaltrials@apellis.com",[26,40,51,63,74,85,94,105,116,125,136,145],{"facility":27,"status":28,"city":29,"state":30,"zip":31,"country":32,"countryCode":33,"cosmosGeoPoint":34,"geoPoint":39,"contacts":11},"Children's Hospital of Atlanta","RECRUITING","Atlanta","Georgia","30329","United States","US",{"type":35,"coordinates":36},"Point",[37,38],-84.38798,33.749,{"lat":38,"lon":37},{"facility":41,"status":42,"city":43,"state":11,"zip":44,"country":45,"countryCode":11,"cosmosGeoPoint":46,"geoPoint":50,"contacts":11},"Motol University Hospital","COMPLETED","Prague","150 06","Czechia",{"type":35,"coordinates":47},[48,49],14.42076,50.08804,{"lat":49,"lon":48},{"facility":52,"status":53,"city":54,"state":11,"zip":55,"country":56,"countryCode":57,"cosmosGeoPoint":58,"geoPoint":62,"contacts":11},"Robert-Debré Hospital Paris","NOT_YET_RECRUITING","Paris","75009","France","FR",{"type":35,"coordinates":59},[60,61],2.3488,48.85341,{"lat":61,"lon":60},{"facility":64,"status":28,"city":65,"state":11,"zip":66,"country":67,"countryCode":68,"cosmosGeoPoint":69,"geoPoint":73,"contacts":11},"Hospital Ampang","Ampang","68000","Malaysia","MY",{"type":35,"coordinates":70},[71,72],101.76667,3.15,{"lat":72,"lon":71},{"facility":75,"status":42,"city":76,"state":11,"zip":77,"country":78,"countryCode":79,"cosmosGeoPoint":80,"geoPoint":84,"contacts":11},"Radboud University Hospital Nijmegen","Nijmegen","6525 GA","Netherlands","NL",{"type":35,"coordinates":81},[82,83],5.85278,51.8425,{"lat":83,"lon":82},{"facility":86,"status":28,"city":87,"state":11,"zip":88,"country":78,"countryCode":79,"cosmosGeoPoint":89,"geoPoint":93,"contacts":11},"University Medical Center Utrecht","Utrecht","3508 GA",{"type":35,"coordinates":90},[91,92],5.12222,52.09083,{"lat":92,"lon":91},{"facility":95,"status":28,"city":96,"state":11,"zip":97,"country":98,"countryCode":99,"cosmosGeoPoint":100,"geoPoint":104,"contacts":11},"University Children's Hospital","Belgrade","11000","Serbia","RS",{"type":35,"coordinates":101},[102,103],20.46513,44.80401,{"lat":103,"lon":102},{"facility":106,"status":28,"city":107,"state":11,"zip":108,"country":109,"countryCode":110,"cosmosGeoPoint":111,"geoPoint":115,"contacts":11},"University Hospital Vall d'Hebron","Barcelona","E-08035","Spain","ES",{"type":35,"coordinates":112},[113,114],2.15899,41.38879,{"lat":114,"lon":113},{"facility":117,"status":28,"city":118,"state":11,"zip":119,"country":109,"countryCode":110,"cosmosGeoPoint":120,"geoPoint":124,"contacts":11},"University Hospital 12 de Octubre","Madrid","E-28041",{"type":35,"coordinates":121},[122,123],-3.70256,40.4165,{"lat":123,"lon":122},{"facility":126,"status":42,"city":127,"state":11,"zip":128,"country":129,"countryCode":130,"cosmosGeoPoint":131,"geoPoint":135,"contacts":11},"Phramongkutklao Hospital and College of Medicine","Bangkok","10400","Thailand","TH",{"type":35,"coordinates":132},[133,134],100.50144,13.75398,{"lat":134,"lon":133},{"facility":137,"status":28,"city":138,"state":11,"zip":139,"country":129,"countryCode":130,"cosmosGeoPoint":140,"geoPoint":144,"contacts":11},"Maharaj Nakorn Chiang Mai hospital","Chiang Mai","50200",{"type":35,"coordinates":141},[142,143],98.98468,18.79038,{"lat":143,"lon":142},{"facility":146,"status":42,"city":147,"state":11,"zip":148,"country":149,"countryCode":150,"cosmosGeoPoint":151,"geoPoint":155,"contacts":11},"St. Mary's Hospital","London","W2 1NY","United Kingdom","UK",{"type":35,"coordinates":152},[153,154],-0.12574,51.50853,{"lat":154,"lon":153},{"type":157,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100431732","phase-2-a-study-of-pegcetacoplan-in-pediatric-patients-with-paroxysmal-nocturnal-hemoglobinuria-pnh-100431732",false,"NCT04901936","A Study of Pegcetacoplan in Pediatric Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)","An Open Label, Single-Arm, Phase 2 Study to Evaluate the Safety, Pharmacokinetics, and Biologic Activity of Pegcetacoplan in Pediatric Patients With Paroxysmal Nocturnal Hemoglobinuria","Inclusion Criteria:\n\n* Are 12-17 years old at the time of screening\n* Weigh at least 20 kg (approx. 44 lbs)\n* Have the diagnosis of PNH, confirmed by high-sensitivity flow cytometry (granulocyte or monocyte clone \\>10%)\n* EITHER:\n\n  * Not being treated with an approved complement inhibitor (eculizumab or ravulizumab) prior to start of pegcetacoplan dosing, AND have hemolytic anemia. Hemolytic anemia is defined as hemoglobin (Hb) less than the lower limit of normal (Hb \\\u003C LLN) and LDH \\>1.5 times the upper limit of normal (ULN); OR\n  * Currently receiving treatment with an approved complement inhibitor (eculizumab or ravulizumab) AND have evidence of ongoing anemia. Ongoing anemia is defined as Hb \\\u003C LLN and ARC \\> ULN\n* Have a platelet count \\>75,000\u002Fmm3 and an absolute neutrophil count \\>1000\u002Fmm3\n\nExclusion Criteria:\n\n* Are an adult, 18 years of age or older, with PNH\n* Known or suspected hereditary fructose intolerance (HFI)\n* History of hereditary complement deficiency, bone marrow transplant, or meningococcal disease (meningitis, bacteremia or septicemia)\n* Females who are pregnant or breastfeeding","ALL","12 Years","17 Years",{"count":169,"type":170},12,"ESTIMATED","INTERVENTIONAL",[173],"PHASE2","The purpose of this study is to evaluate the safety, effectiveness, and biological activity (how the investigational medication is processed by the body) of pegcetacoplan in 12-17 year-olds (adolescents) who have paroxysmal nocturnal hemoglobinuria (PNH).",[176,177],"Paroxysmal Nocturnal Hemoglobinuria (PNH)","Paroxysmal Hemoglobinuria",[179,180,181,182,183,184,9,185],"Paroxysmal Nocturnal Hemoglobinuria","PNH","Pediatric","Adolescent","Apellis","Anemia, Hemolytic","APL-2","2026-06-23",{"date":188,"type":189},"2026-06-26","ACTUAL",{"date":191,"type":189},"2021-02-04",{"date":193,"type":170},"2028-12",{"name":5,"class":6}]